Cytek Biosciences, Inc.CTKBNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -1.30% | -7.59% | -2.18% | +1.54% | +8.12% |
| Gross Profit Growth | +1.83% | -12.41% | -6.17% | -5.01% | -2.28% |
| EBITDA Growth | -135.40% | +0.00% | +0.00% | -236.63% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | -287.34% |
| Net Income Growth | +75.23% | +0.00% | +0.00% | -682.15% | -557.08% |
| EPS Growth | +74.82% | +0.00% | +0.00% | -695.83% | -561.96% |
| EPS Diluted Growth | +72.45% | +0.00% | +0.00% | -704.23% | -568.32% |
| Weighted Average Shares Growth | -1.15% | -1.97% | -3.43% | -2.64% | -0.80% |
| Weighted Average Shares Diluted Growth | -1.15% | -1.97% | -3.43% | -3.94% | -0.80% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -79.01% | -103.16% | -98.26% | -129.48% | -138.61% |
| Free Cash Flow Growth | -86.24% | -129.27% | -129.36% | -136.68% | -261.97% |
| Receivables Growth | +7.96% | +9.60% | +26.63% | +17.17% | +19.05% |
| Inventory Growth | -27.90% | -17.16% | -1.16% | +10.36% | -100.00% |
| Asset Growth | +1.02% | -1.92% | +1.98% | +0.75% | -7.60% |
| Book Value per Share Growth | +1.86% | -1.36% | +0.47% | +0.87% | -12.94% |
| Debt Growth | +20.37% | +10.46% | +71.89% | +291.03% | +94.08% |
| R&D Expense Growth | -10.54% | -0.72% | -11.75% | -9.37% | -7.83% |
| SG&A Expenses Growth | -6.15% | +6.08% | +7.11% | +18.90% | +40.94% |